In one of the few studies carried out to date on ADAMs as therapy predictive biomarkers, Siewerts et al [60] reported that high levels of mRNA for ADAM9 and 11 but not for ADAM10 or ADAM12 were associated with increased benefit from tamoxifen in patients with recurrent breast cancer [60]. The gene discussed is ADAM9; the disease is breast carcinoma.